Clinical Trials Browser

Phase 2 × Melanoma × ON 01910 × Clear all

NCT05764395 2024-10-10

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Phase 2 Suspended

Melanoma